🚨 Don’t get burned: 3 critical biotech IPO due diligence steps before you bet on IP
Biotech investing has a way of humbling even the most disciplined investors.
You can underwrite the science, model the cash flows, and still get blindsided—because i…

Biosimilar entry windows aren’t just math problems. They’re risk problems.
In theory, modeling a biosimilar launch window is a clean exercise: map exclusivities, interpret regulatory timelines, estimate launch readiness, and translate it all into a d…

Generic & biosimilar development is a chess game—your patent landscape is the board.
Before you file, ask the question that determines whether you win, pivot, or burn months (and millions): Do we actually have a viable path through the patent thick…

Designing Around the Moat: How Generic Developers Can Win the Secondary-Patent Game
In generic drug development, the first patent is rarely the whole story.
Yes, the “primary” patent often grabs the headlines—those big, foundational claims that can blo…

Your pharmaceutical portfolio has a time bomb in it. Patent expiration data tells you where.
If you’re running a pharma portfolio, you already know the headline risk: patents expire, generics arrive, and revenue curves bend—sometimes fast. But the real…

Big Pharma doesn’t just defend patents—it builds a wall around them.
And for years, the playbook has been familiar: flood the zone with legal filings, overwhelm with technicalities, and rely on the fact that most outsiders don’t have the time—or the da…

Brands don’t launch “competition” by accident. They do it to control the rules of the game.
In pharma, the most consequential battles often happen in the fine print—especially around authorized generics (AGs).
DrugPatentWatch’s latest piece on the “Aut…